Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 192

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Gene Expression Profiling for Molecular Characterization of Inflammatory Breast Cancer and Prediction of Response to Chemotherapy

Open access
Bertucci, François, Finetti, Pascal, Rougemont, Jacques, Charafe-Jauffret, Emmanuelle, Nasser, Valéry, Loriod, Béatrice, Camerlo, Jacques, Tagett, Rebecca, Tarpin, Carole, Houvenaeghel, Gilles, Nguyen, Catherine, Maraninchi, Dominique, Jacquemier, Jocelyne, Houlgatte, Rémi, Birnbaum, Daniel, Viens, Patrice·2004·Cancer Research

Abstract

Inflammatory breast cancer (IBC) is a rare but aggressive form of breast cancer with a 5-year survival limited to ∼40%. Diagnosis, based on clinical and/or pathological criteria, may be difficult. Optimal systemic neoadjuvant therapy and accurate predictors of pathological response have yet to be defined for increasing response rate and survival. Using DNA microarrrays containing ∼8,000 genes, we profiled breast cancer samples from 81 patients, including 37 with IBC and 44 with noninflammatory breast cancer (NIBC). Global unsupervised hierarchical clustering was able to some extent to distinguish IBC and NIBC cases and revealed subclasses of IBC. Supervised analysis identified a 109-gene set the expression of which discriminated IBC from NIBC samples. This molecular signature was validated in an independent series of 26 samples, with an overall performance accuracy of 85%. Discriminator genes were associated with various cellular processes possibly related to the aggressiveness of IBC, including signal transduction, cell motility, adhesion, and angiogenesis. A similar approach, with leave-one-out cross-validation, identified an 85-gene set that divided IBC patients with significantly different pathological complete response rate (70% in one group and 0% in the other group). These results show the potential of gene expression profiling to contribute to a better understanding of IBC, and to provide new diagnostic and predictive factors for IBC, as well as for potential therapeutic targets.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-04-2696

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 192

Metadata

Authors
Bertucci, F., Finetti, P., Rougemont, J., Charafe-Jauffret, E., Nasser, V., Loriod, B., Camerlo, J., Tagett, R., Tarpin, C., Houvenaeghel, G., Nguyen, C., Maraninchi, D., Jacquemier, J., Houlgatte, R., Birnbaum, D., & Viens, P.
Venue
Cancer Research
Published
2004-12-01
Volume
64
Issue
23
Pages
8558-8565
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2096694106
Cited by
192
References
2
FWCI
7.10
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Gene Expression Profiling for Molecular Characterization of Inflammatory Breast Cancer and Prediction of Response to Chemotherapy. https://app.cochat.ai/papers/10.1158/0008-5472.can-04-2696
The paper
Bertucci, F., Finetti, P., Rougemont, J., Charafe-Jauffret, E., Nasser, V., Loriod, B., Camerlo, J., Tagett, R., Tarpin, C., Houvenaeghel, G., Nguyen, C., Maraninchi, D., Jacquemier, J., Houlgatte, R., Birnbaum, D., & Viens, P. (2004). Gene Expression Profiling for Molecular Characterization of Inflammatory Breast Cancer and Prediction of Response to Chemotherapy. Cancer Research. https://doi.org/10.1158/0008-5472.can-04-2696

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.